STOCK TITAN

Fortress Biotech (FBIO) DEF 14A Filings

FBIO NASDAQ

Here are the DEF 14A proxy statements from Fortress Biotech, Inc. (FBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow FBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBIO filings page.

Rhea-AI Summary

Fortress Biotech, Inc. is holding its 2026 Annual Meeting of Stockholders as a completely virtual event on June 17, 2026 at 10:00 a.m. ET via webcast at www.virtualshareholdermeeting.com/fbio2026, accessible with a 16-digit control number.

Stockholders will vote on two main items: electing seven directors to one-year terms and ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. Only holders of record on April 21, 2026 may vote, and proxies can be submitted by internet, telephone or mail, with the ability to revoke and vote live at the meeting.

The proxy describes a board of seven members, five of whom are independent under Nasdaq rules, and outlines audit, compensation, and nominating committee structures. It details executive pay, including a long-term incentive plan for senior leaders that can grant up to 1% of outstanding shares annually, and reports that the CEO beneficially owns about 19.5% of the common stock, while all directors and officers as a group hold about 28.5%. The filing also discloses 2025 audit fees to KPMG and related-party and management services arrangements with partner companies.